Lung Cancer Clinical Trials in Phoenix

Showing 361-380 of 618 trials

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

NCT04863248

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in the 2nd or 3rd line setting.

Metastatic Non-Small Cell Lung CancerNSCLCLung Cancer

G1 Therapeutics, Inc.10 participantsStarted Apr 2021

Phoenix, Arizona, United States • Los Angeles, California, United States • Rancho Mirage, California, United States +9 more locations

TERMINATEDPhase 1< 1 mile

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

NCT03455556

This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other places in the body. Monoclonal antibodies, such as anetumab ravtansine and atezolizumab, may interfere with the ability of tumor cells to grow and spread.

Mesothelin PositiveStage III Non-Small Cell Lung Cancer AJCC v7Stage IIIA Non-Small Cell Lung Cancer AJCC v7+2 more

Mayo Clinic1 participantsStarted Aug 2018

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Safety Study of SEA-CD40 in Cancer Patients

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Other Conditions in Phoenix